CardioMEMS device implantation is feasible and safe in selected adults and children with congenital heart disease, though further multi-center studies are needed to demonstrate efficacy.
Is the CardioMEMS HF System feasible and safe for monitoring pulmonary arterial pressure in children and patients with congenital heart disease?
The use of the CardioMEMS device for remote pulmonary artery pressure monitoring is feasible and safe in selected patients with congenital heart disease, though larger studies are needed to prove efficacy in reducing hospitalizations.
The CardioMEMS HF System (Abbott, Abbott Park, IL) is the first FDA- and CE-Mark-approved device for monitoring patients with heart failure, significantly reducing hospitalizations and improving the quality of life for NYHA class III non-congenital adult patients. This device, implanted percutaneously, allows the direct monitoring of pulmonary arterial pressure with the wireless transfer of pressure data to the clinician, who can adjust the therapy remotely. Limited experience exists regarding its use in patients with congenital heart disease (CHD). CardioMEMS device implantation is feasible and safe in selected adults and children with CHD. The potential of the device to reduce heart failure hospitalizations in this population is enormous, but further multi-center studies are needed to demonstrate its efficacy.
Piccinelli et al. (Fri,) conducted a review in Congenital heart disease. CardioMEMS HF System was evaluated. CardioMEMS device implantation is feasible and safe in selected adults and children with congenital heart disease, though further multi-center studies are needed to demonstrate efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: